The authors concluded that GRPr and PSMA-based imaging may have a complimentary role to fully characterize prostate cancer disease, GRPr being targeted in low-metastatic-risk patients while PSMA could be a valuable target in higher risks. Here, GRPR is linked to prostate carcinoma.